
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Biotherapeutics that allow for inhaled delivery and months of room-temperature stability are made possible with spray-drying techniques.






